Vanguard Group Inc Amylyx Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,498,028 shares of AMLX stock, worth $36.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,498,028
Previous 4,116,512
9.27%
Holding current value
$36.9 Million
Previous $14.6 Million
97.86%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AMLX
# of Institutions
142Shares Held
75.8MCall Options Held
212KPut Options Held
40.6K-
Adage Capital Partners Gp, L.L.C. Boston, MA8.8MShares$72.2 Million0.1% of portfolio
-
Perceptive Advisors LLC New York, NY7.9MShares$64.9 Million2.22% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.94MShares$48.8 Million7.77% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.54MShares$37.2 Million0.07% of portfolio
-
Saturn V Capital Management LLC Austin, TX3.26MShares$26.8 Million8.47% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $481M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...